Globally, more than 5.5 million people are bitten by venomous snakes every year, leading to an estimated 125,000 deaths and 3 times as many amputations. The problem is most prevalent in Sub-Saharan Africa where affordability of antivenom is low, resulting in only 2% of snakebite victims receiving treatment. Since the introduction of antivenoms in the 1890’s, only modest advances in antivenom technology and production have been made. Current antivenoms are, therefore, still being produced by immunisation of large ruminants, typically horses, with snake venoms and subsequently bleeding them to collect blood comprising venom-specific antibodies . The incompatibility of these antivenoms with the human immune system canlead to serious adverse effects. A novel approach is needed in order to introduce safer, cheaper and more efficacious antivenoms that are compatible with the human immune system to the market.Figure 2: Phage display is a screening technique whereby peptides are displayed on the surface of bacteriophages, some of which bind with high affinity to snake toxins that are attached to plate wells.We attempt to discover cross-reactive,peptide-based antitoxins against the structurally similar dendrotoxins α-dendrotoxin (α-Dtx, UniProtKBP00980), isolated from Dendroaspisangusticeps (Green mamba), and dendrotoxin I (Dtx I, UniProtKBP00979) from Dendroaspis polylepis (Black mamba) by phage display [5,6].Cross-reactive antitoxins with theability to neutralise several toxins are of interest to antivenom development,since only a few cross-reactive antitoxins would be needed to neutralise a complete snake venom.
|Number of pages||1|
|Publication status||Published - 2014|
|Event||GRØN DYST: DTU’s studiekonference om bæredygtighed, klimateknologi og miljø - Danmarks Tekniske Universitet, Lyngby Campus, Denmark|
Duration: 27 Jun 2014 → 27 Jun 2014
Conference number: 3
|Location||Danmarks Tekniske Universitet|
|Period||27/06/2014 → 27/06/2014|